Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 02, 2023

Atezolizumab Plus Magrolimab, Niraparib, or Tocilizumab for Platinum-Refractory Metastatic Urothelial Carcinoma

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Atezolizumab Plus Magrolimab, Niraparib, or Tocilizumab in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Randomized Umbrella Study
Clin. Cancer Res 2023 Aug 31;[EPub Ahead of Print], A Drakaki, T Powles, A Bamias, J Martin-Liberal, SJ Shin, T Friedlander, D Tosi, C Park, C Gomez-Roca, F Joly Lobbedez, D Castellano, R Morales-Barrera, I Moreno-Candilejo, A Flechon, K Yuen, D Rishipathak, K DuPree, F Young, F Michielin, CS Shemesh, EE Steinberg, P Williams, JL Lee

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading